Sep 27, 2023 • 9:05 am EDT Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Sep 19, 2023 • 8:00 am EDT Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Aug 8, 2023 • 8:00 am EDT Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 31, 2023 • 8:00 am EDT Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
May 31, 2023 • 8:00 am EDT Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
May 9, 2023 • 8:00 am EDT Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 1, 2023 • 8:00 am EDT Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting
Apr 18, 2023 • 8:00 am EDT Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target
Apr 17, 2023 • 8:30 am EDT Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting